Alnylam Pharma gets $10m under Takeda alliance
The payment triggers from the transferring of Alnylam‘s RNA interference drug technology to Takeda Pharma for the development of RNAi therapeutics. Earlier, Alnylam has obtained $140m in upfront
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.